Teva- Pharmaceutical Industries Ltd. - ADR

Consistent Growth: Teva Pharmaceutical reported a 5% year-over-year increase in revenue, totaling $3.9 billion, marking the ninth consecutive quarter of growth. This growth is primarily driven by strong sales in innovative brands Austedo (up 39%), Ajovy (up 26%), and Uzedy (doubling to $39 million).

Forecast and Targets: Teva aims to achieve $2.5 billion in sales for Austedo by 2027, underpinned by a strategic focus on its innovative product pipeline, including upcoming submissions for olanzapine and further development of duvakitug. The company confirmed a path toward a 30% operating profit margin by 2027 through targeted cost savings of approximately $700 million.

Challenges with Generics: The generic segment showed muted growth of 3%, primarily due to comparisons with previous years with many launches. The upcoming loss of revenue from generic Revlimid in 2026 will pose challenges, though some of this will be offset by operational efficiencies and ongoing innovations.